Skip to content

Clinical efficacy of heat-sensitive moxibustion combined with wenfei huaxian recipe in the treatment of fibrotic interstitial lung disease - A large sample, multicentre, randomised controlled trial

Clinical efficacy of heat-sensitive moxibustion combined with wenfei huaxian recipe in the treatment of fibrotic interstitial lung disease - A large sample, multicentre, randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069781
Enrollment
Unknown
Registered
2023-03-24
Start date
2023-03-29
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial lung disease with pulmonary fibrosis

Interventions

Experimental group:heat-sensitive moxibustion combined with wenfei huaxian recipe
Control group:Pirfenidone Capsules

Sponsors

The Affiliated Hospital of Jiangxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Meeting the clinical diagnostic criteria for interstitial lung disease with interstitial fibrotic changes. 2.Acupoint thermal sensitivity within the two lateral lines of the dorsal foot and solar bladder meridian, in the area between the two horizontal lines of the lung and diaphragm points, or in the area between the first and second intercostal spaces of the anterior chest from the inside out to within 6 inches. 3.Age = 18 years, no restriction on gender. 4.patients can correctly express the sensation of moxibustion. 5.voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.patients being treated with medications that have a clear efficacy in interstitial fibrosis of the lung, such as Tanshinone IIA sodium sulfonate, lanosterone injection, corticosteroids or immunosuppressive drugs. 2.combination of serious primary or end-stage disease of the heart, brain, liver or kidney. 3.complicated respiratory failure requiring tracheal intubation and invasive ventilator-assisted breathing. 4.children, pregnant and lactating women. 5.allergy to the ingredients of the drug. 6.intolerance to mugwort. 7.mental illness, unable to cooperate with the study. 8.unwilling to provide personal information and are unable to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
FVC% change from baseline;

Secondary

MeasureTime frame
Chinese Medicine Symptom Score;Respiratory distress score;St George's Breathing Questionnaire score;6 minutes walking distance;forced expiratory volume in one second;total lung capacity;carbon monoxide diffusion;partial pressure of oxygen;partial pressure of carbon dioxide;oxygen saturation;

Countries

China

Contacts

Public ContactLiangji Liu, Jun Xiong

The Affiliated Hospital of Jiangxi University of Chinese Medicine

llj6505@163.com15870673696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026